Product Description
TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the _-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity. (Sourced from: https://clinicaltrials.gov/ct2/history/NCT02980029?V_2=View)
Mechanisms of Action: Fatty Acid Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Non-alcoholic SteatohepatitisFast Track - Non-alcoholic Steatohepatitis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ascletis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Hungary, Poland, Puerto Rico, United States
Active Clinical Trial Count: 15
Highest Development Phases
Phase 3: Acne Vulgaris|Fatty Liver, Alcoholic|Glioblastoma|Hepatitis, Alcoholic|Liver Cirrhosis|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis
Phase 2: Non-Small-Cell Lung Cancer|Non-alcoholic Fatty Liver Disease
Phase 1: Healthy Volunteers|Liver Cirrhosis, Alcoholic|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FASCINATE-3 | P3 |
Not yet recruiting |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2030-12-01 |
|
| FASCINIT | P3 |
Not yet recruiting |
Liver Diseases, Alcoholic|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2026-06-01 |
|
| NCT05743621 | P1 |
Recruiting |
Prostate Cancer |
2025-11-01 |
|
| ASC40-304 | P3 |
Recruiting |
Acne Vulgaris |
2025-10-15 |